Knobias Clip Report (07-17-2008) BVTI
Submitted By Knobias ClipReport
BVTI: Reports Clinically & Statistically Significant Data from Phase 3 Trial of BiovaxID
Biovest International, Inc. (BVTI) announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID(R) (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma, an often fatal blood cancer. Originally developed and advanced into human clinical trials by the NCI, BiovaxID is designed to recruit the immune system to recognize and destroy only cancerous B-cells. Based on this study’s highly encouraging clinical evidence reporting on vaccinated patients to date, including efficacy and safety, Biovest intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the U.S. and European Union, respectively.
Visit 1800blogger to see all of our industry leading blogs.
